# Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

> **NCT00069992** · PHASE2 · TERMINATED · sponsor: **Baylor College of Medicine** · enrollment: 7 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **RADIATION:** Total Body Irradiation
- **DRUG:** Fludarabine
- **DRUG:** Campath 1H

## Key facts

- **NCT ID:** NCT00069992
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-12
- **Primary completion:** 2006-09
- **Final completion:** 2007-04
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Closed due to competing protocols
- **Last updated:** 2012-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069992, "Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00069992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*